Contact
Novalysin AB
Ideon Science Park
Scheelevägen 32
223 63 Lund
mats.clarsund@novalysin.com
Company
Novalysin AB focus on developing lysin based therapeutic candidates for treatment of antibiotic-resistant tuberculosis and mycobacterial skin infections.
Novalysin AB was founded in 2020 by Adel Abouhmad, Rajni Hatti-Kaul and Mats Clarsund based on ground-breaking and innovative design of potent anti-mycobacterial peptides at Lund University and Ghent University.
